Mounjaro weight-loss drug price to almost triple in UK after Trump complaint

The price of the popular weight Mounjaro will almost triple After WE-The companies have equalized market costs around the world.

One month of supply of the highest doses of “King Kong“Weight loss drugs will drop from £ 122 to £ 330 – an increase of 170%.

At least 500,000 people in the UNITED KINGDOM Take Mounjaro or WegovyAnother weight stroke, via private online pharmacies, according to retailers.

In June, the NHS Mounjaro offered obese patients after health experts calculated from NHS data in England according to which there were 97,500 patients who would benefit from the treatment.

The owner of Mounjaro, Eli Lily, said that he would not increase the price paid by the NHS, and that he was working with private health care providers to maintain access to the JAB.

This decision reflects how the pharmaceutical industry sails in policy changes in the United States, by far its most lucrative market.

This comes after the administration of Donald Trump complained of “foreign freeladers” that count on the United States to pay more for medicine.

Last month, he would have written to the leaders of pharmaceutical companies, including Eli Lilly, asking them to match the prices of American prescription drugs with what is paid abroad.

The United States pays more for prescription drugs than any other country, often almost three times more than other developed nations.

Eli Lilly Launched Mounjaro In the United Kingdom in February of last year, while the treatment of Wegovy de Novo Nordisk Rival has been available in the country since September 2023.

The company said that when it launched Mounjaro in the United Kingdom, it has accepted a list price “significantly below “ that in its three other European markets to avoid delays in availability via the NHS.

“We are now lining up the list of the list more regularly,” said a spokesperson.

In the United Kingdom, the NHS was invited to offer Mounjaro to patients with a BMI of more than 40 and at least four clinical conditions related to their weight, such as heart disease or type 2 diabetes.

Over the next three years, around 240,000 patients should be eligible for treatment.

He came after the National Institute for Health and Care Excellence (Nice) warned that many people could regain weight if they are not adequately supported after ceasing treatment.

He pointed out that those who come out of drugs should be offered “structured advice and follow -up support” to mitigate weight gain. These guidelines apply to people receiving these treatments via the NHS.

Nice’s new “quality standard” said NHS patients should be monitored for at least one year after treatment, and additional support should be offered if necessary.

It emphasizes the creation of “long -term behavioral habits, to use self -surveillance tools and to rely on wider support – from online communities to family and local interventions”.

This standard, a type of advice for health services in England and Wales, defines expectations for health providers, including how they should support patients.

Weight loss injections, also known as the GLP-1 receptors, work by imitating the natural hormone that regulates blood sugar, appetite and digestion.